Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients
Basel, Switzerland, November 1 (ots/PRNewswire) - - Three New Studies Presented at AASLD Demonstrate Efficacy and Safety of Extended Treatment in Non-Responders, Relapsers and Slow-Responders Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by ...